(Q33964560)

30 July 2017

1 reference

title

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review (English)

1 reference

30 July 2017

1 reference

1 reference

5

David J Kupfer

1 reference

30 July 2017

1

John R Geddes

1 reference

30 July 2017

7

Guy M Goodwin

1 reference

30 July 2017

6

Ellen Frank

1 reference

30 July 2017

2

Stuart M Carney

1 reference

30 July 2017

Christina Davies

3

1 reference

30 July 2017

Toshiaki A Furukawa

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

30 July 2017

1 reference

30 July 2017

volume

361

1 reference

30 July 2017

issue

9358

1 reference

30 July 2017

page(s)

653-661

1 reference

Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Recognition and management of depression in general practice: consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, reinfarction and side-effects from 33 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Executive dysfunction and long-term outcomes of geriatric depression.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Recurrence of depression after discontinuation of long-term amitriptyline treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Unipolar depression in the elderly. Reoccurrence on discontinuation of tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Continuation Therapy with Amitriptyline in Depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Use of phenelzine in continuation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Sertraline in the prevention of depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Three-year outcomes for maintenance therapies in recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Gepirone in the treatment of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Maintenance Phase Efficacy of Sertraline for Chronic Depression A Randomized Controlled Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Prophylactic effect of mianserin on recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Treatment of Depression by Drugs and Psychotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Maintenance therapy for chronic depression. A controlled clinical trial of desipramine.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Five-year outcome for maintenance therapies in recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Continuation therapy with tricyclic antidepressants in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Citalopram 20 mg, citalopram 40 mg and placebo in the prevention of relapse of major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Prevention of recurrent depressive episodes with milnacipran: consequences on quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Maintenance therapy with amitriptyline: a controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Discontinuing antidepressant treatment in major depression

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Recurrence of mania after lithium withdrawal. Implications for the use of lithium in the treatment of bipolar affective disorder.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Risk of Recurrence Following Discontinuation of Lithium Treatment in Bipolar Disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Rapid recurrence of mania following abrupt discontinuation of lithium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912599-8

7 January 2021

10.1016/S0140-6736(03)12599-8

Identifiers

DOI

1 reference

30 July 2017

1 reference